- Home
- MDBH vs CMRX Comparison
MDBH vs CMRX Comparison
Compare MDBH & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDBH
- CMRX
- Stock Information
- Founded
- MDBH 1997
- CMRX 2000
- Country
- MDBH United States
- CMRX United States
- Employees
- MDBH N/A
- CMRX N/A
- Industry
- MDBH
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- MDBH
- CMRX Health Care
- Exchange
- MDBH Nasdaq
- CMRX Nasdaq
- Market Cap
- MDBH 66.8M
- CMRX 77.1M
- IPO Year
- MDBH 2023
- CMRX 2013
- Fundamental
- Price
- MDBH $6.50
- CMRX $3.34
- Analyst Decision
- MDBH
- CMRX Strong Buy
- Analyst Count
- MDBH 0
- CMRX 2
- Target Price
- MDBH N/A
- CMRX $8.50
- AVG Volume (30 Days)
- MDBH 8.0K
- CMRX 11.7M
- Earning Date
- MDBH 11-12-2024
- CMRX 11-07-2024
- Dividend Yield
- MDBH N/A
- CMRX N/A
- EPS Growth
- MDBH N/A
- CMRX N/A
- EPS
- MDBH N/A
- CMRX N/A
- Revenue
- MDBH $1,937,885.00
- CMRX $159,000.00
- Revenue This Year
- MDBH N/A
- CMRX N/A
- Revenue Next Year
- MDBH N/A
- CMRX $1,690.28
- P/E Ratio
- MDBH N/A
- CMRX N/A
- Revenue Growth
- MDBH N/A
- CMRX N/A
- 52 Week Low
- MDBH $5.78
- CMRX $0.75
- 52 Week High
- MDBH $13.25
- CMRX $3.39
- Technical
- Relative Strength Index (RSI)
- MDBH 47.55
- CMRX 86.13
- Support Level
- MDBH $6.00
- CMRX $2.71
- Resistance Level
- MDBH $6.27
- CMRX $3.20
- Average True Range (ATR)
- MDBH 0.24
- CMRX 0.35
- MACD
- MDBH -0.00
- CMRX 0.11
- Stochastic Oscillator
- MDBH 51.82
- CMRX 98.05
About MDBH MDB Capital Holdings LLC common
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.